Nymox NicAlert Product Can Help Smoking Cessation.

MAYWOOD, N.J. -- The smoking cessation market presents an attractive opportunity for Nymox Pharmaceutical's (NASDAQ: NYMX) tobacco exposure test, NicAlert(TM), according to Brian Doyle, the Company's Global Sales Manager. NicAlert(TM) provides a proven, easy-to-use, on-site means of determining the level of an individual's use of or exposure to tobacco products. NicAlert(TM) has received U.S. FDA clearance for medical use for determining an individual's exposure to tobacco products such as cigarettes, pipes, or chewing tobacco within the past 48 hours.

"NicAlert(TM) offers a cost-effective way of determining smoking status right on-site," said Mr. Doyle. "It does not require any special instruments or skills and gives accurate results within minutes. We believe that it can be a valuable tool in the campaign to get smokers to quit before it is too late."

Reducing the estimated 1.3 billion number of smokers worldwide is a major goal of the WHO Framework Convention on Tobacco Control. The WHO estimates that tobacco use and exposure currently kills 4.9 million people a year worldwide with the annual death toll rising to an estimated 10 million by 2020. In the U.S. alone, the Centers for Disease Control and Prevention (CDC) estimates that smoking causes over 440,000 premature deaths annually and creates an economic loss of over $150 billion a year.

The benefits of smoking cessation programs was demonstrated by a recent study that tracked the health of 5887 smokers for more than 14 years as part of the Lung Health Study (Ann Intern Med. 2005 Feb 15;142:233-9). More than 4 times as those smokers who were enrolled in a smoking cessation program were not smoking after 5 years as compared to those smokers not offered the program (21.7% vs. 5.4%). After 14.5 years, the death rate for those who managed to quit was 46% lower than that of the people who continued to smoke.

NicAlert(TM)'s a powerful one-step technology has been found by independent peer-reviewed studies to be an accurate, rapid and cost-effective means of confirming smoking status. One study, "Validating a Dipstick Method for Detecting Recent Smoking," Cancer Epidemiology, Biomarkers & Prevention (2002; 11: 1123-1125) was authored by Peter Gariti of the University of Pennsylvania Cancer Center Group, Philadelphia Veterans Affairs Medical Center and the University of Pennsylvania School of Medicine, David I. Rosenthal of the M.D. Anderson Cancer Center in Houston, Kathleen Lindell of the University of Pittsburgh and John Hansen-Flaschen, Joseph Shrager, Craig Lipkin, Arthur I. Alterman and Lawrence R. Kaiser of the University of Pennsylvania School of Medicine. The study examined the smoking status of patients at a cancer clinic and found that the results obtained using Nymox's tobacco product exposure test had an "excellent agreement" with state-of-the-art sophisticated laboratory measurements but at a substantially lower cost (over 90% less). The second study, "The Accuracy of Self-Reported Smoking Status Assessed by Cotinine Test Strips," Nicotine & Tobacco Research (2002; 4: 305-9) was authored by Donna R. Parker, ScD, and Thomas M Lasater, PhD, Brown University School of Medicine; Richard Windsor, PhD, MPH, George Washington University Medical Center; Jeff Wilkins, MD, Greater Los Angeles VA Healthcare Center, David Upegui, BA, Memorial Hospital of Rhode Island; and James Heimdal, PhD, The Hoffman Heart Institute, Saint Francis Hospital and Medical Center, Hartford, CT. The study found Nymox's product to be "an inexpensive and rapid method to routinely biochemically confirm smoking status at a clinical visit." The authors described the Nymox product as a "simple, inexpensive and rapid measure to immediately confirm smoking status in field settings."

Nymox's patented technology provides a semi-quantitative measure of cotinine, a byproduct of the body's metabolism of nicotine. Cotinine is widely accepted and commonly used in medical research and public health studies to determine the extent of tobacco product exposure.

More information about Nymox is available at www.nymox.com, email: [e-mail], or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The conduct of clinical trials and the development of drug products involve substantial risks and uncertainties and actual results may differ materially from expectations. Promising early results do not ensure that later stage or larger scale clinical trials will be successful or will proceed as expected. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.